An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA

Trial Profile

An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors sanofi pasteur MSD
  • Most Recent Events

    • 29 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov.
    • 11 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov record.
    • 23 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top